Cholesterol and APOE genotype interact to influence Alzheimer disease progression - PubMed (original) (raw)
Clinical Trial
Cholesterol and APOE genotype interact to influence Alzheimer disease progression
R M Evans et al. Neurology. 2004.
Abstract
In this retrospective analysis of 443 Alzheimer disease (AD) patients from a 30-week tacrine trial, change in Alzheimer's Disease Assessment Scale score from baseline to final value was significantly associated with a total serum cholesterol/APOE genotype interaction. Disease progression in the no-APOE epsilon4 allele/high-cholesterol subgroup was greater than in the normal-cholesterol subgroups with or without epsilon4. Cholesterol levels and APOE genotype may interact to affect AD progression. The results are consistent with preclinical data on cholesterol's effects in AD.
Similar articles
- Tacrine and rate of progression in Alzheimer's disease--relation to ApoE allele genotype.
Sjögren M, Hesse C, Basun H, Köl G, Thostrup H, Kilander L, Marcusson J, Edman A, Wallin A, Karlsson I, Troell M, Wachtmaister G, Ekdahl A, Olofsson H, Sandström A, Andreasen N, Minthon L, Blennow K. Sjögren M, et al. J Neural Transm (Vienna). 2001;108(4):451-8. doi: 10.1007/s007020170066. J Neural Transm (Vienna). 2001. PMID: 11475012 Clinical Trial. - Apolipoprotein E genotype and gender influence response to tacrine therapy.
Farlow MR, Lahiri DK, Poirier J, Davignon J, Hui S. Farlow MR, et al. Ann N Y Acad Sci. 1996 Dec 16;802:101-10. doi: 10.1111/j.1749-6632.1996.tb32603.x. Ann N Y Acad Sci. 1996. PMID: 8993489 Clinical Trial. - Cholesterol, APOE genotype, and Alzheimer disease: an epidemiologic study of Nigerian Yoruba.
Hall K, Murrell J, Ogunniyi A, Deeg M, Baiyewu O, Gao S, Gureje O, Dickens J, Evans R, Smith-Gamble V, Unverzagt FW, Shen J, Hendrie H. Hall K, et al. Neurology. 2006 Jan 24;66(2):223-7. doi: 10.1212/01.wnl.0000194507.39504.17. Neurology. 2006. PMID: 16434658 Free PMC article. - Alzheimer's disease: clinical implications of the apolipoprotein E genotype.
Farlow MR. Farlow MR. Neurology. 1997 May;48(5 Suppl 6):S30-4. doi: 10.1212/wnl.48.5_suppl_6.30s. Neurology. 1997. PMID: 9153158 Review. - Cholesterol and apoe: a target for Alzheimer's disease therapeutics.
Fenili D, McLaurin J. Fenili D, et al. Curr Drug Targets CNS Neurol Disord. 2005 Oct;4(5):553-67. doi: 10.2174/156800705774322085. Curr Drug Targets CNS Neurol Disord. 2005. PMID: 16266288 Review.
Cited by
- Brain insulin dysregulation: implication for neurological and neuropsychiatric disorders.
Ghasemi R, Dargahi L, Haeri A, Moosavi M, Mohamed Z, Ahmadiani A. Ghasemi R, et al. Mol Neurobiol. 2013 Jun;47(3):1045-65. doi: 10.1007/s12035-013-8404-z. Epub 2013 Jan 20. Mol Neurobiol. 2013. PMID: 23335160 Review. - Cholesterol level, statin use and Alzheimer's disease in adults with Down syndrome.
Zigman WB, Schupf N, Jenkins EC, Urv TK, Tycko B, Silverman W. Zigman WB, et al. Neurosci Lett. 2007 Apr 18;416(3):279-84. doi: 10.1016/j.neulet.2007.02.023. Epub 2007 Feb 11. Neurosci Lett. 2007. PMID: 17353095 Free PMC article. - The "Alzheimer's disease signature": potential perspectives for novel biomarkers.
Davinelli S, Intrieri M, Russo C, Di Costanzo A, Zella D, Bosco P, Scapagnini G. Davinelli S, et al. Immun Ageing. 2011 Sep 20;8:7. doi: 10.1186/1742-4933-8-7. Immun Ageing. 2011. PMID: 21933389 Free PMC article. - Insight into the Molecular Imaging of Alzheimer's Disease.
Arora A, Bhagat N. Arora A, et al. Int J Biomed Imaging. 2016;2016:7462014. doi: 10.1155/2016/7462014. Epub 2016 Jan 10. Int J Biomed Imaging. 2016. PMID: 26880871 Free PMC article. Review. - Religious education and midlife observance are associated with dementia three decades later in Israeli men.
Beeri MS, Davidson M, Silverman JM, Schmeidler J, Springer RR, Noy S, Goldbourt U. Beeri MS, et al. J Clin Epidemiol. 2008 Nov;61(11):1161-8. doi: 10.1016/j.jclinepi.2007.09.011. Epub 2008 Jun 6. J Clin Epidemiol. 2008. PMID: 18538995 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous